Sanofi ($SNY) won a badly needed FDA approval Wednesday for its oral multiple sclerosis drug Aubagio (teriflunomide). And soon after the news hit a representative for Sanofi subsidiary Genzyme said that the MS treatment will be priced at $45,000 a year, angling in to grab market share.
http://www.fiercebiotech.com/story/sanofi-snags-fda-ok-oral-ms-drug-aubagio/2012-09-12
